We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+6.12%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.93B
AUM Growth
-$220M
(-10%)
Cap. Flow
-$774M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
143
New
28
Increased
19
Reduced
29
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$75.2M |
| 2 |
Humana
HUM
|
+$40.6M |
| 3 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$30.6M |
| 4 |
DaVita
DVA
|
+$28.5M |
| 5 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$25.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$51.8M |
| 2 |
AstraZeneca
AZN
|
+$48.2M |
| 3 |
AbbVie
ABBV
|
+$45M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$35M |
| 5 |
THOR
THORATEC CORPORATION
THOR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.08% |
| 2 | Financials | 1.16% |
| 3 | Technology | 0.74% |
| 4 | Industrials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PTLA
26
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $21.3M | 1.1% |
825,675
+706,227
| +591% | +$17.2M |
|
|
SPPI
27
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $20.9M | 1.08% |
2,361,405
-670,345
| -22% | -$5.99M |
|
|
MNTA
28
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $20.1M | 1.04% |
1,136,645
-871,241
| -43% | -$14.6M |
|
|
KERX
29
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $19.2M | 1% |
1,483,260
-2,366,036
| -61% | -$28.3M |
|
30
Centene
CNC
$32.8B
| $18.4M | 0.96% |
+1,251,248
| New | +$18.7M |
|
31
Insmed
INSM
$23.6B
| $17.9M | 0.93% |
1,052,245
+121,495
| +13% | +$1.86M |
|
|
AGN
32
DELISTED
Allergan Inc
AGN
| $16.9M | 0.87% |
152,000
-32,955
| -18% | -$3.15M |
|
33
Viatris
VTRS
$20.1B
| $16.6M | 0.86% |
382,000
-396,000
| -51% | -$16.3M |
|
|
RNA
34
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
| $14.6M | 0.75% |
3,119,381
-105,143
| -3% | -$479K |
|
|
AIRM
35
DELISTED
Air Methods Corp
AIRM
| $14.3M | 0.74% |
245,292
-435,269
| -64% | -$21.7M |
|
|
36
CALL
Teva Pharmaceuticals
TEVA
$36.6B
| $14M | 0.73% |
350,000
| – | – |
|
37
Prothena Corp
PRTA
$450M
| $14M | 0.73% |
+528,705
| New | +$13.3M |
|
|
ASRT
38
DELISTED
Assertio
ASRT
| $13.3M | 0.69% |
21,011
-4,072
| -16% | -$1.99M |
|
39
Integra LifeSciences
IART
$1.48B
| $13M | 0.67% |
+665,575
| New | +$12.2M |
|
|
NSPH
40
DELISTED
NANOSPHERE INC. COM NEW
NSPH
| $10.9M | 0.56% |
237,346
-19,815
| -8% | -$830K |
|
|
NSTG
41
DELISTED
NanoString Technologies, Inc.
NSTG
| $10.8M | 0.56% |
624,711
+128,061
| +26% | +$1.58M |
|
|
BDSI
42
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $10.4M | 0.54% |
1,760,725
-856,861
| -33% | -$4.42M |
|
|
LITS
43
Lite Strategy Inc
LITS
$34.7M
| $10M | 0.52% |
62,726
+21,616
| +53% | +$3.7M |
|
44
PTC Therapeutics
PTCT
$6.49B
| $9.25M | 0.48% |
545,027
-300,000
| -36% | -$5.27M |
|
|
BLUE
45
DELISTED
bluebird bio
BLUE
| $8.88M | 0.46% |
32,673
| – | – |
|
|
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
| $8.84M | 0.46% |
321,250
-239,081
| -43% | -$5.36M |
|
|
FMI
47
DELISTED
Foundation Medicine, Inc.
FMI
| $8.24M | 0.43% |
+346,018
| New | +$9.67M |
|
|
WINT
48
DELISTED
Windtree Therapeutics Inc
WINT
| $8.23M | 0.43% |
261,407
+176,550
| +208% | +$5.52M |
|
49
Alphatec Holdings
ATEC
$1.29B
| $8.01M | 0.41% |
331,895
| – | – |
|
50
Vanda Pharmaceuticals
VNDA
$322M
| $7.83M | 0.41% |
631,276
-188,724
| -23% | -$1.9M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2013 Portfolio in Review
As of Q4 2013, Deerfield Management held 143 positions worth $1.93B, down 10% from $2.15B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management withdrew a net $774M in Q4 2013, closing 37 positions and reducing 29 holdings. Its most notable exit was Pfizer, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Humana worth $42.8M.
- Deerfield Management's largest Q4 2013 buy was Humana: 414,670 shares worth $42.8M.
- Deerfield Management added most to QUESTCOR PHARMA INC in Q4 2013, an estimated $75.2M increase.
- Deerfield Management's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $35M.
- Deerfield Management fully exited Pfizer in Q4 2013, selling an estimated $51.8M.
- Deerfield Management's ten largest holdings make up 35% of its $1.93B portfolio in Q4 2013.
- Deerfield Management opened 28 new positions and closed 37 in Q4 2013.
- Deerfield Management's portfolio value fell 10% quarter-over-quarter to $1.93B.
Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.